A Billion-Dollar Aldosterone Synthase Inhibitor, an Oral KRASG12D Inhibitor Entering Development, and 14 More Molecules in the News

In this article, you'll find a curated selection of >70 molecules from August that piqued our interest, highlights of some of our favorites, and explanations of why they're worth watching.

In this roundup, we present a curated selection of over 50 molecules from October that captured our team’s interest. We highlight our top picks and offer insights into what makes them stand out.

Our October patent highlights cover a diverse array of drug discovery IP disclosures. From piperidine-based USP19 inhibitors and small molecule GIPR antagonists for obesity to KCC2 potentiators for epilepsy, the month delivered a number of exciting IP developments. Other notable discoveries include MTA-cooperative PRMT5 inhibitors, direct-acting influenza antivirals against a novel target, Nrf2 activators for heart failure, and a slew of Polθ inhibitors for HR-deficient cancers.

This summary of September's major clinical updates features FDA approvals, drug withdrawals, anticipated regulatory decisions, notable trial results, new NDA submissions, clinical trial setbacks, and the initiation of new clinical trials.

This summary of major clinical updates from November 2024 covers FDA approvals, the initiation of new clinical trials, notable trial outcomes for key drug candidates, and news on paused and discontinued trials and programs.